Exploration of Targeted Anti-tumor Therapy

Table 3

Comparison of clinico-pathological features between patients with good and poor ALI

Parameter		Total	ALI		P-value
Parameter		Total	Good (> 28.02)	Poor (≤ 28.02)	P-value
BMI	< 18.5%	285	9	47	0
	18.5–24.99%		59	102
	25.0–29.99%		34	27
	≥ 30%		6	1
Smoker	Yes	285	22	37	0.91
Smoker	No	285	86	140	0.91
Age	≤ 65 Years	285	94	158	0.57
Age	> 65 Years	285	14	19	0.57
SMD	Good (> 36.62)	285	42	58	0.29
SMD	Poor (≤ 36.62)	285	66	119	0.29
Gender	Male	285	55	104	0.20
Gender	Female	285	53	73	0.20
Sarcopenia	Yes	285	55	107	0.12
Sarcopenia	No	285	53	70	0.12
mALI	Good (> 55.33)	285	95	17	0
mALI	Poor (≤ 55.33)	285	13	160	0
NLR	Good (≤ 3)	285	94	16	0
NLR	Poor (> 3)	285	14	161	0
Chemotherapy regimen received	Geftinib	285	51	92	0.44
Chemotherapy regimen received	Pemetrexed plus platins	285	57	85	0.44
Grades of drug toxicity	High grade	273	61	109	0.62
Grades of drug toxicity	Low grade	273	40	63	0.62
Performance status	0–1	285	103	165	0.46
Performance status	≥ 2	285	5	12	0.46
Progression	Yes	285	78	132	0.66
Progression	No	285	30	45	0.66
Final status	Alive	285	33	34	0.03
Final status	Dead	285	75	143	0.03

Bold values indicate significant P-values